EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Road Not Taken: Misclassifying an Anti‐Seizure Medication as a Failure

Christopher N Henry iD, Daniel M Goldenholz iD

Annals of Clinical and Translational Neurology · 2025

DOI: 10.1002/acn3.70139 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von Christopher N Henry und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Children's Hospital of Richmond at VCU Health, Virginia, United States. Hauptthemen laut MEDLINE: Anticonvulsants, Seizures. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To quantify how often anti‐seizure medications (ASMs) appear ineffective yet provide benefit when considering seizure frequency (SF) variability.

Methods

We used the CHOCOLATES seizure diary simulator to generate 100,000 patient seizure diaries that reflect natural SF variation in a heterogeneous population. Medication effect was modeled as a 20% average SF reduction (standard deviation 10%). We identified how many patients with an observed ≥ 25% SF increase (apparent worsening) actually had a true ≥ 10% SF reduction (vs. no medication), and how many with an observed ≥ 50% SF reduction (apparent responders) would have shown < 0% reduction if not taking the ASM. We also quantified how many individuals who had apparent worsening were actual worsening (> 0% SF increase vs. no medication).

Results

Simulations closely matched real‐world ASM trials, showing a median SF reduction of 36% with ASM versus 17% with placebo; 35% of patients on ASM achieved ≥ 50% SF reduction versus 20% on placebo. Apparent worsening occurred in 12%; among these, 76% were true improvers. Of the apparent responders, 12% were true nonresponders. Only 4% of the individuals with apparent worsening truly worsened compared to no medication.

Interpretation

SF variability can lead to significant misclassification of ASM benefit. Many patients labeled as having “failed” an ASM trial were likely receiving meaningful benefit and may warrant reconsideration of the medication. Prospective clinical studies are needed to determine how best to account for SF variability and refine the interpretation of treatment response in epilepsy management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsSeizuresHumansTreatment FailureAdultMaleFemaleMiddle Aged

Stichwörter der Autor:innen

anti‐seizure medicationbioinformaticsepilepsysimulationstatistics

Substanzen

Anticonvulsants

Autor:innen und Institutionen

  • Department of Neurology, Children's Hospital of Richmond at VCU Health, Virginia, United States.
  • Beth Israel Deaconess Medical Center, Department of Neurology, United States.
  • Harvard Medical School, United States.

ORCID-Profile: Christopher N Henry, Daniel M Goldenholz

Förderung

  • NINDS NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Henry, C. N., & Goldenholz, D. M. (2025). The Road Not Taken: Misclassifying an Anti‐Seizure Medication as a Failure. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70139

Vancouver

Henry CN, Goldenholz DM. The Road Not Taken: Misclassifying an Anti‐Seizure Medication as a Failure. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.70139

BibTeX
@article{Henry2025,
  author = {Henry, Christopher N and Goldenholz, Daniel M},
  title = {The Road Not Taken: Misclassifying an Anti‐Seizure Medication as a Failure},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2025},
  doi = {10.1002/acn3.70139}
}
Kostenlos starten →